📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3 — Appendices & Regional (3.2.A/3.2.R) (OBX-319)

Document ID: M3-AR
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4Q; Q3D

Appendices & Regional Information (3.2.A / 3.2.R) — OBX-319

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that co-engages CD19 and CD20 on B lymphocytes, expressed in a Chinese hamster ovary (CHO) cell line, purified by a Protein A capture and orthogonal polishing train, and formulated for subcutaneous administration. The appendix and regional content below is presented in the ICH M4Q(R1) common technical document structure and reflects the biologics-specific expectations of ICH Q5A(R2), Q5C, Q5D, Q5E, Q6B, and S6(R1), together with the U.S. regional expectations for a Biologics License Application submitted under Section 351(a) of the Public Health Service Act and 21 CFR Part 601. Because OBX-319 is a recombinant antibody rather than a small molecule, the appendix content is centred on cell-substrate provenance, adventitious-agent and viral safety, and control of the product- and process-related variants that are characteristic of an asymmetric heterodimeric bispecific.

3.2.A Appendices

This section addresses facilities and equipment (GMP status of the manufacturing sites), adventitious-agents safety (cell-line history, viral safety, and viral-clearance validation), and novel excipients if any.

3.2.A.1 Facilities and Equipment

The drug substance is manufactured by upstream CHO fed-batch cell culture followed by harvest clarification and the downstream Protein A / polishing purification train; the drug product is aseptically filled and assembled into the subcutaneous presentation at a dedicated fill-finish site. Both the drug-substance and drug-product sites operate under a current-Good-Manufacturing-Practice pharmaceutical quality system consistent with ICH Q7, Q10, and 21 CFR Parts 210/211 and 600–680, hold valid manufacturing authorisations, and are named in the application as the sites of manufacture, testing, packaging, and release for OBX-319.

A facility and equipment description, floor-plan and personnel/material/product/waste flow diagrams, and a room-classification summary are provided to demonstrate that unidirectional flows and appropriate air-handling (ISO 5 aseptic core within an ISO 7 background for the filling operation) prevent mix-ups and cross-contamination. Because the sites are multi-product, a documented cross-contamination control strategy is included: predominant use of single-use (disposable) bioreactor and chromatography flow-path technology to eliminate shared product contact, segregation of the OBX-319 cell-culture and purification suites in time and/or space, campaign manufacture with validated changeover and line-clearance procedures, and cleaning validation for the shared stainless-steel and multi-use equipment that remains (including a health-based swab/rinse acceptance limit derived from the antibody's carry-over risk and demonstration that the protein is denatured/degraded by the alkaline clean-in-place cycle). Closed and functionally-closed processing, environmental and utility (water-for-injection, clean steam, process gases) monitoring, and a shared-equipment matrix are provided to support the conclusion that concurrent manufacture of other products does not adversely affect OBX-319 quality.

3.2.A.2 Adventitious-Agents Safety Evaluation

A comprehensive adventitious-agents safety evaluation is provided in accordance with ICH Q5A(R2), Q5D, and Q6B, covering the cell-substrate history, the testing of the cell banks and of unprocessed bulk, and the validated capacity of the purification process to clear potential viral contaminants.

Cell-substrate history and characterisation. OBX-319 is produced from a clonally-derived recombinant CHO cell line generated by transfection with the expression construct encoding the two heavy chains and the light chain(s) of the bispecific antibody; the derivation history of the parental CHO line, the transfection and clone-selection strategy, and the vector are documented. A two-tiered, fully characterised Master Cell Bank (MCB) and Working Cell Bank (WCB) system is established under ICH Q5D. Characterisation includes identity (isoenzyme and/or genetic identity), copy number and genetic stability of the construct across and beyond the proposed limit of in-vitro cell age used for production, and adventitious-agent testing of the MCB, WCB, and post-production (end-of-production) cells. The genetic-stability and end-of-production-cell data support the limit of in-vitro cell age.

Non-viral adventitious agents. The cell-culture process is animal-component-free: a chemically-defined, serum-free medium is used and no raw materials of human or animal (ruminant) origin are employed, minimising the risk of introducing adventitious agents and satisfying the transmissible-spongiform-encephalopathy expectations of Ph. Eur. 5.2.8 / the CHMP TSE Note for Guidance and 9 CFR requirements; TSE/BSE certification of any biologically-sourced ancillary materials is provided. Routine in-process controls for bioburden, bacterial endotoxin, and mycoplasma (culture and/or nucleic-acid-based methods) are applied to the cell banks, the pre-harvest/unprocessed bulk, and defined in-process pools, and the drug product is released as sterile with a container-closure-integrity control strategy.

Viral safety. The viral-safety assurance rests on the three complementary pillars of ICH Q5A(R2): (i) selection and testing of source materials and cell banks for the absence of detectable adventitious viruses; (ii) testing of the unprocessed bulk at an appropriate limit each production run using in-vitro adventitious-virus assays and, as applicable, next-generation-sequencing-based broad detection; and (iii) demonstration of the manufacturing process's capacity to remove and inactivate virus. As a CHO-derived product, OBX-319 harbours non-infectious endogenous retrovirus-like particles (RVLP), which are quantified in the unprocessed bulk by transmission electron microscopy and by a reverse-transcriptase / infectivity assay; the estimated particle load is used to calculate the safety margin.

Viral-clearance validation. Dedicated small-scale spiking studies, performed under a validated scale-down model and conducted in accordance with ICH Q5A(R2), quantify log10 reduction values (LRV) for a panel of model viruses spanning size, genome type, and envelope: xenotropic murine leukaemia virus (X-MuLV, an enveloped RNA retrovirus that models the endogenous RVLP), a non-enveloped DNA parvovirus (minute virus of mice, MVM, the worst-case small non-enveloped model), an enveloped DNA virus (pseudorabies, PRV), and a non-enveloped RNA virus (reovirus type 3, Reo-3). The purification train provides multiple orthogonal clearance mechanisms: the low-pH hold following Protein A capture inactivates enveloped viruses (X-MuLV ≥ 4.5 log10; PRV ≥ 4 log10), the anion-exchange polishing step operated in flow-through mode removes both enveloped and non-enveloped species (X-MuLV ≥ 4 log10; MVM ≥ 4 log10), and dedicated small-virus nanofiltration (20 nm) provides robust size-based removal (X-MuLV ≥ 5 log10; MVM ≥ 4 log10), with Protein A chromatography contributing additional enveloped-virus removal. Cumulative clearance of the retrovirus model exceeds 18 log10 and of the parvovirus model exceeds 9 log10; the cumulative retrovirus-clearance capacity exceeds the RVLP load estimated in the unprocessed bulk by a wide safety margin (in excess of six logs of over-clearance), supporting the conclusion that the finished product presents a negligible retroviral risk.

3.2.A.3 Excipients / Novel Excipients

The subcutaneous formulation comprises well-established, compendial (USP-NF / Ph. Eur.) parenteral excipients only: a histidine/histidine-hydrochloride buffer for pH control, a stabilising sugar (sucrose), a non-ionic surfactant (polysorbate) to protect against interfacial and agitation stress, and, as applicable, an amino-acid tonicity/viscosity modifier for the high-concentration subcutaneous presentation. All excipients have a well-documented history of use at or above the levels employed here in approved parenteral biologic products; each is controlled to a compendial monograph with additional supplier and functionality-related characterisation as needed. There are no novel excipients in OBX-319, and accordingly no separate novel-excipient safety qualification package is required.

3.2.R Regional

This section provides the region-specific quality information: executed-batch and comparability information, the container-closure and, for the device presentation, the medical-device / combination-product particulars, the elemental impurities risk assessment (ICH Q3D), and a nitrosamine risk assessment, together with the U.S.-specific content expected for a BLA. ICH M4Q; Q3D; Q5A(R2).

3.2.R.1 Executed Batch Records and Batch Analyses

Representative executed batch records for the drug substance and the drug product are provided, together with the batch-analysis summaries for the process-performance-qualification (PPQ) lots and for the clinical lots used in Study OBX319-301. Three consecutive commercial-scale PPQ lots of drug substance and of drug product were manufactured within the validated process parameter ranges and met all in-process, release, and characterisation acceptance criteria, demonstrating a state of control and reproducible manufacture at scale. The genealogy linking the pivotal Phase 3 material to the intended commercial process is tabulated so that the reviewer can trace the material used to generate the OBX319-301 efficacy and safety database to the licensed process.

3.2.R.2 Comparability

A comparability exercise conducted in accordance with ICH Q5E documents the process changes introduced across development (including cell-culture scale-up to the commercial single-use bioreactor train and any site or process refinements) and demonstrates that pre- and post-change material are comparable with respect to primary structure, the bispecific-specific higher-order and assembly attributes, charge and size heterogeneity, glycosylation, potency, and the process-related impurity profile. Particular analytical attention is paid to the chain-pairing–related product variants that are unique to an asymmetric heterodimeric IgG1 bispecific — correctly-assembled bispecific versus homodimers, half-antibodies, and mispaired species — which are monitored by orthogonal methods (for example intact and reduced/subunit mass spectrometry, and hydrophobic-interaction and imaged capillary isoelectric focusing) and shown to be controlled and comparable across the change history. The comparability conclusion is supported by side-by-side release, extended-characterisation, and forced-degradation/stability data; no in-vivo or clinical bridging beyond the analytical and functional comparability package was required to support the changes.

3.2.R.3 Container-Closure System

The primary container-closure system for the subcutaneous presentation is a single-dose glass primary container fitted with an elastomeric closure and a fluoropolymer-laminated stopper, selected for compatibility with the high-concentration antibody formulation. Container-closure-integrity is demonstrated by a validated deterministic (e.g., headspace or high-voltage) method in lieu of a microbial-ingress challenge, and an extractables-and-leachables assessment (informed by USP <1663>/<1664>) evaluates the container, closure, and, where applicable, silicone-oil lubricant and residual tungsten, confirming that leachables remain below toxicological and product-quality thresholds over the shelf life. Suitability of the container-closure system is supported by the stability program (ICH Q5C) including storage in the inverted/on-side orientation.

3.2.R.4 Medical-Device / Combination-Product Particulars

The marketed subcutaneous presentation is a drug-device combination product as defined in 21 CFR 3.2(e), and the application includes the combination-product content required under 21 CFR Part 4. Device design and development are documented under design controls (21 CFR 820.30 / ISO 13485), including design inputs and outputs, verification and validation, and a design history file summary. Essential-performance and functional testing (dose accuracy and delivered volume, injection/glide and activation forces, break-loose behaviour, and needle-safety functionality for the delivery device) is provided, along with biocompatibility of patient-contacting materials per ISO 10993 and a human-factors / usability-engineering summary aligned with the FDA human-factors guidance and IEC 62366-1 demonstrating that the intended users can safely and effectively self-administer the subcutaneous dose. A shelf-life for the assembled combination product is supported by the drug-product stability program.

3.2.R.5 Elemental Impurities Risk Assessment (ICH Q3D)

An elemental-impurities risk assessment was performed for the parenteral route in accordance with ICH Q3D(R2). Potential contributors — the cell-culture raw materials and media components, water, the chromatography resins and buffers, single-use and stainless-steel product-contact surfaces, excipients, and the container-closure system — were evaluated against the parenteral permitted daily exposures for the 24-elemental panel, including the Class 1 elements (As, Cd, Hg, Pb), the Class 2A elements (Co, Ni, V), and the Class 3 and other elements. No elemental catalysts or reagents are intentionally added in the manufacture of OBX-319. Confirmatory analysis of representative drug-substance and drug-product batches by ICP-MS showed that the summed contribution for each element at the maximum clinical daily dose is well below the parenteral control threshold (below 30% of the applicable permitted daily exposure). The risk is therefore assessed as low and no additional routine elemental-impurity specification or control is warranted beyond the existing compendial controls on incoming materials and water.

3.2.R.6 Nitrosamine Risk Assessment

A nitrosamine risk assessment was conducted consistent with the current FDA and ICH M7-related guidance. OBX-319 is a recombinant protein produced by cell culture and purification rather than by chemical synthesis; there is no small-molecule synthetic route employing nitrosating agents together with vulnerable secondary or tertiary amines, so the formation of small-molecule nitrosamine impurities and of nitrosamine drug-substance-related impurities (NDSRIs) is not applicable to the active substance. The assessment therefore focused on residual potential sources — trace amines or nitrite in excipients, water, and processing aids, and potential contributions from the container-closure and manufacturing materials. Each was evaluated and judged to present negligible risk under the process and storage conditions, and no nitrosating conditions are present. On this basis no confirmatory nitrosamine testing or additional control is required; the documented risk assessment is retained and will be reviewed if the process, formulation, or materials change.

3.2.R.7 United States Regional Information (21 CFR Part 601)

The U.S.-specific regional content supporting the BLA under Section 351(a) of the PHS Act and 21 CFR Part 601 is provided, including the executed batch records and certificates of analysis for the U.S. release lots, the lot-release protocol and the sponsor's approach to any FDA lot-release requirements applicable to the product, the methods-validation package, and the environmental assessment or a claim of categorical exclusion under 21 CFR 25.31. Consistent with the biologic modality, no genotoxicity, carcinogenicity, hERG, or thorough-QT information is included in this regional section, as those assessments are not warranted for a monoclonal antibody of this class.